Pyxis Oncology Consolidates Leadership with Permanent CEO and Chairman Appointment
PYXS has more than doubled off its 52-week low of $1.03 on elevated volume (1.8× avg).
Summary
Pyxis Oncology appointed Thomas Civik as permanent CEO and Chairman, effective September 4, 2026, consolidating leadership ahead of key MICVO clinical data readouts expected in Fall 2026 and Q4 2026.
Key Events · Executive and Board Changes · PYXS
-
Civik Named Permanent CEO and Chairman
Effective September 4, 2026, Thomas Civik—who has served as Interim CEO since February 2, 2026—was appointed permanent CEO and Chairman of the Board, combining both roles.
-
Board Leadership Restructured
John Flavin transitioned from Chairman to Lead Independent Director and Chair of the Compensation Committee; Dr. Santhosh Palani resigned, reducing the Board from eight to seven members.
-
CEO Equity Award
Civik received a nonqualified stock option to purchase 2,503,050 shares, vesting 25% on the first anniversary and the remainder in 36 equal monthly installments, plus a $100,000 sign-on bonus.
-
Clinical Timelines Reaffirmed
Updated MICVO Phase 1 monotherapy data expected in Fall 2026; Phase 1/2 combination data with pembrolizumab expected in Q4 2026.
Analysis · PYXS · Life Sciences
With key clinical milestones approaching for its lead asset MICVO, Pyxis Oncology has moved to consolidate leadership by making Thomas Civik's interim CEO role permanent and combining it with the Chairman position. To preserve oversight, the board appointed co-founder John Flavin as Lead Independent Director, while director Santhosh Palani resigned citing time commitments. The company also reiterated its clinical timeline: updated MICVO Phase 1 monotherapy data in Fall 2026 and Phase 1/2 combination data in Q4 2026. The CEO option grant of 2.5 million shares is a meaningful equity award but vests over four years, so near-term dilution is limited.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYXS was trading at $3.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $324.5M. The 52-week trading range was $1.03 to $5.55. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.